Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment

Journal of Neurosciences in Rural Practice

Volumn 6, Issue 1, 2015, Pages 17-22

  Wani, Rayees Ahmad ^a   Dar, Mansoor Ahmad ^a   Margoob, Mushtaq Ahmad ^a   Rather, Yasir Hassan ^a   Haq, Inaamul ^b   Shah, Majid Shafi ^a  

^a Departments of Psychiatry   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Antipsychotic agents; Diabetes mellitus; Glucose tolerance test; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 84908544590     PISSN: 09763147     EISSN: 09763155     Source Type: Journal    
DOI: 10.4103/0976-3147.143182     Document Type: Article

References (37)

1. Martin EA."Schizophrenia" Concise Medical Dictionary. Oxford United kingdom 8th Edition: Oxford University Press, Maastricht University Library; 2010. p. 411.
2. Lawrence D, Holman C, Jablensky A. Preventable Physical Illness in People with Mental Illness. Perth: University of Western Australia; 2001.
3. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: A record linkage study. Can J Psychiatry 1991; 36:239-45.
4. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment, the metabolic syndrome. Life Sci 2002;71:239-57.
5. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118 Suppl 2 15s-22s.
6. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-11.
7. Proakis AG, Mennear JH, Miya TS, Borowitz JL. Phenothiazine-induced hyperglycemia: Relation to CNS and adrenal effects. Proc Soc Exp Biol Med 1971;137:1385-8.
8. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA. 1956;162:1651.
9. Cooperberg AA, Eidlow S. Hemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy. Can Med Assoc J 1956;75:746-9.
10. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968;29:827-8.
11. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:978-82.
12. Hägg S, Joelsson L, Mjörndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9.
13. Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35:1381-7.
14. Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997;171:90-1.
15. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
16. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998;59:687-9.
17. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999;156:970.
18. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-43.
19. Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922;8:184-96.
20. Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945;102:108-10.
21. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 1946;56:74-8.
22. Langfeldt G. The insulin tolerance test in mental disorders. Acta Psychiatr Neurol Scand Suppl 1952;80:189-99.
23. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495.
24. Adams PF, Marano MA. Vital and Health Statistics. Current Estimates from the National Health Interview Survey, 1994. Hyattsville, MD: National Center for Health Statistics; 1995. p. 82-89.
25. Longo DL, Fausi AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill Medical; 2008. p. 2275.
26. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: Are we any closer to understanding the link? J Psychopharmacol 2005;19 Suppl 6:56-65.
27. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-45.
28. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003;10:348-55.
29. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20:368-78.
30. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
31. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-70.
32. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-71.
33. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects. Neuro psychopharmacology 2007;32:289-97.
34. Clark NG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
35. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-15.
36. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
37. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.